The Peroxiredoxin 1 (PRDX1) gene maps to chromosome arm 1p and is hemizygously deleted and epigenetically silenced in isocitrate dehydrogenase 1 or 2 (IDH)-mutant and 1p/19q-codeleted oligodendroglial tumors. In contrast, IDH-wildtype astrocytic gliomas including glioblastomas mostly lack epigenetic silencing and express PRDX1 protein. In our study, we investigated how PRDX1 contributes to the infiltrative growth of IDH-wildtype gliomas. Focusing on p38a-dependent pathways, we analyzed clinical data from 133 patients of the NOA-04 trial cohort to look for differences in the gene expression profiles of gliomas with wildtype or mutant IDH. Biochemical interaction studies as well as in vitro and ex vivo migration studies were used to establish a biological role of PRDX1 in maintaining pathway activity. Whole-brain high-resolution ultramicroscopy and survival analyses of pre-clinical mouse models for IDH-wildtype gliomas were then used for in vivo confirmation. Based on clinical data, we found that the absence of PRDX1 is associated with changes in the expression of MET/HGF signaling components. PRDX1 forms a heterodimer with p38a mitogen-activated protein kinase 14 (MAPK14), stabilizing phospho-p38a in glioma cells. This process amplifies hepatocyte growth factor (HGF)-mediated signaling and stimulates actin cytoskeleton dynamics that promote glioma cell migration. Whole-brain high-resolution ultramicroscopy confirms these findings, indicating that PRDX1 promotes glioma brain invasion in vivo. Finally, reduced expression of PRDX1 increased survival in mouse glioma
Introduction
A hallmark of gliomas is their diffusely infiltrative growth into the adjacent neuropil. 1 Mutations affecting codon 132 in the isocitrate dehydrogenase 1 (IDH1) or codon 172 in the IDH2 gene (IDH mutation) as well as codeletion of the chromosomal arms 1p and 19q (1p/19q codeletion) are diagnostic markers to separate biologically and prognostically distinct groups of diffuse astrocytic and oligodendroglial tumors in adults according to the World Health Organization (WHO) classification of tumors of the central nervous system. 2 The gene locus encoding peroxiredoxin 1 (PRDX1) is located on chromosome band 1p34 and was found to be hemizygously deleted and epigenetically silenced in 1p/19q-codeleted oligodendroglial tumors. 3 This anti-oxidant enzyme forms homodimers in which both subunits are linked via a disulfide bond between the peroxidatic cysteine (Cys51) of one subunit and the resolving cysteine (Cys172) of the other subunit. 4 Recent studies have shown that PRDX1 may also act as a molecular chaperone, a function that requires Cys83. 5 CpG island (CGI) hypermethylation and reduced expression of PRDX1 have been detected in 1p/19q-codeleted oligodendroglial gliomas and a subset of secondary glioblastomas, as opposed to primary glioblastomas that mostly lacked PRDX1 hypermethylation. 6 In vitro data suggested that loss of PRDX1 expression may contribute to more favorable response of gliomas to DNA-alkylating chemotherapy with temozolomide. 6 However, the underlying molecular mechanisms are unknown.
The yeast homolog of PRDX1, Tpx1, has been found to activate the p38a homolog Sty1 by forming a disulfide heterodimer. 7 Increased p38a activity has been associated with advanced stages of tumor progression and decreased survival of patients with solid cancers. 8 In addition to proliferation, p38a supports cell migration by phosphorylating MAP kinase-activated protein kinase 2 (MK2) which, in turn, phosphorylates the actin-capping heat shock protein 27 (HSP27). 9 The phosphorylation of HSP27 reduces its affinity for F-actin. This change increases the number of barbed ends that are available for actin polymerization, which is required for the cells to form lamellipodia and filopodia for migration. 10 Pathological activation of the receptor tyrosine kinase proto-oncogene mesenchymal-epithelial transition factor (MET) is an adverse prognostic factor in gliomas, and inhibition of MET or its autocrine-produced ligand hepatocyte growth factor (HGF) has been suggested as a promising treatment strategy. 11, 12 Aberrant MET/HGF signaling enhances proliferation, promotes angiogenesis and prevents apoptosis. 13 Moreover, MET/HGF also drives the invasion of tumor cells by activating MAP kinases, such as p38a.
14 This signaling further amplifies itself in a positive feedback loop by increasing the expression of proteases essential for the maturation of precursors of MET and HGF. 15 Thus, stratifying subgroups of glioma patients who might respond to HGF/MET inhibition could be important for successful targeted therapies.
Here, we identified a novel molecular pathomechanism involving PRDX1 that is relevant to therapy resistance of glioma. We demonstrate that PRDX1 acts as a potent amplifier of p38a signaling, which is essential for sustaining MET/ HGF-driven glioma cell invasion.
Materials and Methods

Reagents
Drugs, antibodies and shRNAs used in our study are listed in the Supporting Information.
Cell culture
Established glioma cell lines (LN229, LN308, Hs683) 16 and patient-derived low-passaged glioma cells (NCH270, NCH354) isolated from native tumor tissues 17 were extensively characterized as described previously. Cells were cultured under humidified air conditions with 5% (v/v) CO 2 at 378C in DMEM (Sigma Aldrich, Munich, Germany) containing 5% (v/v) fetal calf serum (Biochrome, Munich, Germany). Cell toxicity was assessed with the Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher, Frankfurt, Germany). The detailed method is provided in the Supporting Information.
Recombinant proteins
Proteins were produced in BL21 bacteria (Novagen, Munich, Germany) using the pET28 expression system and purified
What's new?
The peroxiredoxin 1 (PRDX1) gene frequently is silenced by epigenetic mechanisms in gliomas with 1p/19q codeletion or mutated isocitrate dehydrogenase 1 or 2 (IDH). By contrast, PRDX1 is strongly expressed in IDH-wildtype gliomas. This study shows that PRDX1 forms a heterodimer with p38a, which sustains p38a phosphorylation in glioma cells. High p38a phospholevels were found to amplify MET proto-oncogene/hepatocyte growth factor (HGF) signaling and to stimulate dynamic actin cytoskeleton remodeling, thereby promoting glioma invasion. The findings suggest that patients with gliomas expressing high levels of PRDX1 might benefit from targeted inhibition of the MET/HGF signaling.
using HisTrap FF columns with Ni Sepharose 6 Fast Flow (GE Healthcare, Munich, Germany). The detailed method is provided in the Supporting Information.
Immunohistochemistry
Immunohistochemistry was performed on sections cut to 4 mm. The samples were stained using a Ventana BenchMark ULTRA immunostainer (Ventana Medical Systems, Oro Valley, USA), pretreated with cell conditioner 2 at pH 6 for 64 min, and followed by incubation with primary antibodies at 378C for 32 min. This procedure was followed by incubation with OptiView HQ Universal Linker for 12 min, incubation with OptiView HRP Multimer for 12 min, incubation with OptiView Amplification for 12 min and incubation with hematoxylin and Bluing reagent for 4 min.
Affinity chromatography
For immune affinity chromatography, immune complexes were purified with protein G-conjugated agarose resin (Roche, Mannheim, Germany). Secreted proteins were isolated from serum-free, conditioned medium by lectin affinity chromatography using Concanavalin A-conjugated agarose resin (Sigma Aldrich, Munich, Germany). The detailed method is provided in the Supporting Information.
Immunoblotting
Proteins were isolated with lysis buffer, separated by discontinued SDS-PAGE and transferred onto PVDF. Proteins were detected using primary antibodies and species-matched HRPcoupled secondary antibodies (Dianova, Hamburg, Germany). The detailed method is provided in the Supporting Information.
Quantitative reverse transcription PCR
DNA from formalin-fixed paraffin-embedded patient tissues was purified from representative tumor areas using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). DNA and RNA were purified from fresh frozen patient tissues and cell lines using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) and the RNeasy MinElute Cleanup Kit (Qiagen, Hilden, Germany).
Methylation analysis
Bisulfite-converted genomic DNA was screened for the CGI methylation status of PRDX1 across six CpGs (measured as five distinct CpGs) using a MassARRAY analyzer (Sequenom, San Diego, USA), as previously described. 18 Sequencing data were analyzed with Epityper 1.05 (Sequenom, San Diego, USA). Methyl-CpG immunoprecipitation with 2.5 lg genomic DNA, array hybridization using CpG island arrays (Agilent, Waldbronn, Germany) and data evaluation were essentially performed as described previously. 19 The detailed method is provided in the Supporting Information.
PRDX1 methylation groups were determined based on optimal cut-point analysis using the maximally selected logrank statistic approach, 20, 21 which corrects for type I error inflation due to multiple testing.
Patients and tumor samples
Glioma tissue samples were acquired from the NOA-04 clinical trial. The clinically related research in this work is covered by the ethics votes for NOA-04. 22 The detailed method is provided in the Supporting Information.
Bioinformatic analysis
Normalized RNAseq TCGA PanCan expression data for PRDX1 and PID-MET pathway genes were downloaded from the Xena browser (UCSC Xena http://xena.ucsc.edu). For heatmap representation, rows (genes) and columns (samples) were clustered using Euclidean distance and Ward's method. The detailed method is provided in the Supporting Information.
To correlate methylation and expression data of investigated candidate genes, methylation (Illumina Human Methylation 450 BeadChip) and clinical data (WHO grade) were obtained from The Cancer Genome Atlas. All statistical tests were two-sided, and a p-values below 0.05 was considered significant. The detailed method is provided in the Supporting Information.
Assessment of actin dynamics
To measure actin fiber length, cells expressing LifeActmCherry were seeded on m-Slide-8-well ibiTreat plates (Ibidi, Martinsried, Germany) and imaged using an UltraVIEW VoX 3D Live Cell Imaging System (Perkin Elmer, Hamburg, Germany), as described previously. 23 The detailed method is provided in the Supporting Information.
Migration assays
For transwell migration assays, 30,000 cells were seeded in transwells (Corning, Wiesbaden, Germany) along a nutrient gradient. Migrated cells were imaged using a Cell Observer microscope (Zeiss, Oberkochen, Germany), recorded using the ZEN 2012 software (Zeiss, Oberkochen, Germany) and counted using ImageJ v1.47 (National Institutes of Health, Bethesda, USA). For real-time cell analysis (RTCA), migration of 80,000 cells was monitored using an xCELLigence RTCA DP analyzer (Acea Biosciences, San Diego, USA). The detailed method is provided in the Supporting Information.
Ex vivo assays
Cytodex 3 microcarriers (GE Healthcare, Uppsala, Sweden) were mixed with 10 6 glioma cells in warm culture medium and incubated for 4 hr at 378C with 5% (v/v) CO 2 overnight. Mouse brains were prepared as described previously. 24, 25 Single coated beads were implanted into subcortical areas. DAPI-stained slices were imaged using a TSC SP5 II confocal microscope (Leica, Frankfurt, Germany). The detailed method is provided in the Supporting Information. For ex vivo invasion assays, tumor spheres from Hs683 cells were placed at the hippocampal dentate gyrus region and incubated for 5 days. Brain slices were imaged in tile scans using a TriM Scope 2-photon microscope (LaVision BioTec, Bielefeld, Germany). The detailed method is provided in the Supporting Information.
Animal experiments
For each treatment group, 12 male NSG mice (Jackson, Bar Harbor, USA), 10-12 weeks of age, were anesthetized and xenografted with 7.5 3 10
4 glioma cells at a position 1 mm lateral and 2 mm posterior from the bregma. All animal procedures were conducted in accordance with the institutional animal research guidelines after obtaining approval from the regional commission of Karlsruhe, Baden-Wuerttemberg, Germany (file number G113/14). Survival was compared using the log-rank test. The detailed method is provided in the Supporting Information.
Ultramicroscopy and quantification of whole mouse brain cell invasion
For ultramicroscopy, the brains were cleared optically as described previously. 26 Dehydration solutions were changed every 24 hr, starting from the highest to the lowest dilution. The tissues were cleared for 48 hr. After clearing, the samples were stored at 48C. The cleared brains were imaged using an UltraMicroscope II (LaVision BioTec, Bielefeld, Germany), as described previously. 27 The detailed method is provided in the Supporting Information.
Results
CpG island methylation (CGI) and reduced expression of PRDX1 correlate with improved overall patient survival Previously, we showed that PRDX1 is affected by the codeletion of the 1p/19q region in gliomas. 3 We found that the 5 0 -CpG island associated with the PRDX1 gene promoter region was frequently methylated and that PRDX1 mRNA expression was reduced in 1p/19q-codeleted oligodendrogliomas and in secondary glioblastomas as compared to primary glioblastomas. 6 Further studies showed that PRDX1 conferred chemo-resistance to temozolomide (TMZ) treatment by improving the cellular anti-oxidative stress response. 6, 28 Here, we analyzed the NOA-04 trial cohort of patients with anaplastic gliomas of WHO grade III 22 to test whether CGI methylation of PRDX1 is prognostic for overall patient survival. Among a total of 133 patients with sufficient molecular information, high PRDX1 CGI methylation correlated with significantly improved overall patient survival (Fig. 1a) , an increased rate of IDH mutation (for IDHwt patient-specific progression free survival see Supporting Information, Fig.  S1a ) and MGMT promoter methylation (Supporting Information, Fig. S1b) . A previous study in yeast found that the PRDX1 homolog Tpx1 affects the phosphorylation of the p38a homolog Sty1. 7 This MAP kinase is an important hub that controls signaling pathways such as MET/HGF which drive infiltrative tumor growth of gliomas. 8 Therefore, we tested whether low levels of PRDX1 would affect p38a activity. Co-deleted gliomas such as oligodendrogliomas often have reduced PRDX1 expression levels due to epigenetic silencing of the remaining allele as compared to noncodeleted gliomas such as astrocytomas. 6 Compared to astrocytomas, we found lower PRDX1 levels in oligodendrogliomas that were accompanied by lower phosphorylation levels of p38a (Fig. 1b) .
Reduced PRDX1 levels are associated with lower expression levels of MET/HGF signaling components Focusing on p38a-dependent signaling pathways, we used the data set from The Cancer Genome Atlas (TCGA) 29 to look for differences in the gene expression profiles of gliomas with wildtype IDH and gliomas with mutant IDH (either 1p/ 19q-codeleted or non-codeleted). As observed for the NOA-04 collective, CGI methylation of PRDX1 correlated with lower gene expression ( Supporting Information, Fig. S1c ). The TCGA data set showed that oligodendroglial tumors with IDH mutation and 1p/19q codeletion had significantly reduced expression of PRDX1 when compared to IDH-wildtype and IDH-mutant astrocytic gliomas (Fig. 1c) . Lower PRDX1 protein levels in IDH-mutant and 1p/19q-codeleted oligodendroglial tumors as opposed to IDH-mutant astrocytomas were confirmed in the NOA-04 cohort (Fig. 1b) . IDHmutated and 1p/19q-codeleted tumors also exhibited reduced gene expression levels of MET adaptors (such as GAB1, SHC1 and GRB2) and effectors (such as RAC1, RHOA and FAK), as well as the MET ligand HGF as demonstrated in the TCGA data set (Fig. 1d) . In addition, a gene-by-gene comparison using a Kruskal-Wallis test with post-hoc FDR p adjustment across glioma subtypes was performed (Supporting Information, Table S1 ). All of these genes were highly expressed in gliomas with wildtype IDH. Most of these effector proteins are involved in tumor invasion. Since the majority of the differentially regulated genes in the MET/HGF pathway did not map to 1p or 19q, we analyzed whether the expression of these genes depends on the expression of PRDX1 in the established cell line LN229 16 and in patientderived low-passaged glioma cells NCH270. 17 Knockdown of PRDX1, using a previously validated shRNA, 6 reduced the levels of the MET adaptor proteins GAB1, SHC1 and GRB2, the MET effector proteins Rac1, RhoA and p-FAK (Supporting Information, Fig. S1d ) as well as the MET ligand HGF ( Supporting Information, Fig. S1e) , thus confirming the TCGA data.
PRDX1 is an amplifier of MET/HGF signaling MET/HGF signaling has been shown to converge on p38a, 13 which is an important signaling pathway for transcriptional regulation and cell migration. 9, 30 We hypothesized that PRDX1 might stabilize phosphorylated p38a (p-p38a) and thus amplify MET/HGF signaling, whereas reduced PRDX1 levels would attenuate this pathway due to reduced levels of MET adaptor and effector proteins. Inhibiting MET using the Molecular Cancer Biology dual MET/vascular endothelial growth factor receptor (VEGFR2) inhibitor foretinib or the selective MET kinase inhibitor PF04217903 reduced the levels of p-p38a in a dosedependent manner ( Supporting Information, Fig. S2a ). However, MET inhibition (Supporting Information, Figs. S2b and S2c) or silencing (Fig. 2a, Supporting Information, Fig. S2d ) in glioma cells did not influence PRDX1 levels. Conversely, while silencing of PRDX1 reduced the levels of p-p38a in all glioma cells, this approach did not affect MET receptor levels (Fig. 2b,  Supporting Information, Fig. S2e ). When we instead overexpressed PRDX1, we detected an increase in p-p38a levels that concomitantly lead to the increase in c-MET phosphorylation, while the total c-MET remained unchanged (Fig. 2e) . Moreover, MET-driven phosphorylation of p38a was partially restored in PRDX1-depleted LN229 cells when the cells were supplied with recombinant HGF (Supporting Information, Fig.  S2f ). Similar to PRDX1 depletion, the knockdown of p38a in LN229 or NCH270 also reduced HGF levels as well as adaptor and effector proteins of the MET pathway (Fig. 2c) . These data imply that PRDX1 supports the MET/HGF signaling network in established and patient-derived, low-passaged glioma cells by stabilizing p-p38a levels.
PRDX1 is a chaperone for phosphorylated p38a
Since previous studies proposed an anti-oxidant-independent chaperone function of PRDX1 via its Cys83 residue, 31 we investigated whether PRDX1 would interact with p38a. We found that WT PRDX1, as well as the catalytically inactive mutants PRDX1 C52S and PRDX1 C172S , co-precipitated with p38a ( Supporting Information, Fig. S2h) . However, the PRDX1 C83S mutant did not co-precipitate with p38a (Fig. 2d) . We confirmed in co-precipitates from LN229 and LN308 cells that endogenous PRDX1 interacts with p38a (Supporting Information, Figs. S2i and S2j). In support of the finding that PRDX1 stabilizes p-p38a levels (Fig. 2b) , we found that PRDX1 C83S acts as a dominant negative mutant by reducing the levels of p-p38a in both established and patient-derived, low-passaged glioma cells (Supporting Information Fig. S2g) .
Similar to the yeast p38a-homolog Sty1, 7 human p38a required the corresponding Cys39 residue to interact with PRDX1, and the p38a C39S mutant was consequently less phosphorylated than WT p38a (Supporting Information, Figs. S2k and S2l). Furthermore, when precipitating p-p38a from lysates of NCH270 glioma cells, we observed PRDX1-p38a heterodimers at approximately 70 kDa under non-reducing conditions; this finding was reminiscent of the Sty1-Tpx1 disulfide dimers that were described previously 7 (Fig. 2f) . Collectively, these data indicate that PRDX1 stabilizes p-p38a by forming heterodimers, which might be important for p38a-dependent regulation of cellular processes, such as cell migration.
Stabilization of p-p38a by PRDX1 is required for glioma cell migration
Since we only found a modestly reduced proliferation ( Supporting Information, Fig. S3a ) and no cytotoxic effects upon PRDX1 knockdown ( Supporting Information, Fig. S3b ), we analyzed whether PRDX1 might regulate the motility of glioma cells via p38a. Previous studies showed that p38a influences the actin cytoskeleton by phosphorylating MK2 and HSP27. 9 First, we assessed the influence of PRDX1 on the dynamics of actin fibers and focal adhesion formation. The rapid assembly and disassembly of the actin meshwork, which supports the formation of focal adhesions, is required for cell motility. 32, 33 By monitoring changes in actin fiber length in LN229 and Hs683 cells (Fig. 3a, Supporting Information, Fig.  S3c ), we found that the dynamics of actin fiber reorganization were significantly reduced in the absence of PRDX1. This effect was phenocopied by the knockdown of p38a (Fig. 3b,  Supporting Information, Fig. S3d ). We also monitored the formation rate of focal adhesions (Fig. 3c, Supporting Information, Fig. S3e) . Accordingly, PRDX1 knockdown reduced the turnover of focal adhesions (Figs. 3d and 3e and Supporting Information, Figs. S3f and S3g). In addition to a decrease in actin fiber and focal adhesion dynamics, we also observed a significant reduction of protrusions in glioma cells after the knockdown of PRDX1 (Fig. 3f, Supporting Information, Fig.  S3h ). Based on these findings, we hypothesized that PRDX1 depletion might also affect cell migration. In transwell assays (Supporting Information, Figs. S3i and S3j) and real-time cell analyses ( Supporting Information, Fig. S3k ), the silencing of PRDX1 significantly reduced cell migration in comparison to controls.
We also studied the invasion of glioma cells on murine organotypic brain slices (Fig. 3g) . In comparison to the control group, PRDX1-depleted LN229 cells formed less infiltrating tumors as indicated by a lower perimeter and a higher circularity (Figs. 3h and 3i) . To further strengthen the link between MET and the role of PRDX1 in invasion we inhibited MET in PRDX1-expressing glioma cells. This significantly reduced their invasion capacity, whereas inhibiting c-MET signaling in PRDX1-depleted cells did not reduce invasion (Figs. 3j and 3k) .
To also assess long-distance migration, we grafted Hs683 glioma cells into the dentate gyrus of murine organotypic hippocampal slices and tracked tumor cell invasion using tiled 2-photon microscopy. In accordance with our previous findings, the control cells invaded further from the original grafting site into the adjacent tissue than glioma cells after PRDX1 knockdown (Supporting Information Figs. S3l and S3m). Taken together, these results indicate that PRDX1 influences the cell motility of glioma cells and thereby the ability of the cells to invade tissue.
Reduced PRDX1 expression prolongs survival and reduces glioma invasion in vivo
To test whether PRDX1 also influences glioma invasion in vivo, knockdown of PRDX1 improved survival compared to that of the control group (shCTR vs. shPRDX1; p < 0.0001), and survival was further improved when PRDX1-depleted xenografts were treated with TMZ (shCTR vs. shPRDX1 1 TMZ, p < 0.0001; shPRDX1 vs. shPRDX1 1 TMZ, p < 0.0001) (Figs. 4a  and 4b) . Using a recently established ultramicroscopy platform 27 ( Fig. 4c) , we studied tumor invasion on the single-cell level. We used whole murine brains that were xenografted with a mixture of DsRed-labeled glioma cells expressing a control shRNA and EGFP-labeled glioma cells expressing a shRNA against PRDX1. Similar to the results obtained with organotypic brain slices, PRDX1 depletion strongly reduced glioma cell invasion into the surrounding parenchyma (Figs. 4d and 4e) . Furthermore, restoring the depleted levels of endogenous PRDX1 in glioma cells using the mutant PRDX1 C83S failed to rescue the invasive capability of the cells in comparison to glioma cells rescued with WT PRDX1 (Figs. 4f and 4g ). The proposed pathway is illustrated in Figure 4h .
Discussion
We previously reported that epigenetic silencing of PRDX1 is frequent in 1p/19q-codeleted oligodendrogliomas and a subset of secondary glioblastomas, both types of glioma that typically carry IDH mutations. 6 Here, we demonstrate that infiltrative growth of IDH-wildtype (and 1p/19q-noncodeleted) gliomas may be promoted by high PRDX1 levels that support MET/HGF-driven invasion. PRDX1 appears to mediate this function by forming heterodimers with p38a, sustaining the phosphorylation of p38a and in turn supports c-MET signaling (Fig. 4h) . The improved overall survival of patients with 1p/19q-codeleted oligodendrogliomas might be explained by the fact that oligodendroglial tumors with IDH mutation and 1p/19q-codeletion exhibit significantly reduced expression of PRDX1 when compared to IDH wildtype and IDH mutant astrocytic gliomas. Since PRDX1 low-expressing IDH1 mutant gliomas also exhibit a strong invasive potential, other factors besides PRDX1 seem to also regulate and contribute to glioma invasion. MET/HGF-independent signaling cascades regulated by PRDX1 such as pathways involved in metabolizing reactive oxygen species may also be involved in cell motility and invasion. 34 Increased CGI methylation of PRDX1 was significantly associated with IDH mutation and correlated with a longer overall patient survival in the NOA-04 clinical trial cohort. This is line with a previous study suggesting that mutant IDH1 induces CGI methylation of PRDX1 in gliomas displaying the CpG island methylator phenotype (CIMP). 35 IDH mutation is seen in a subset of WHO grade IV glioblastomas in younger patients and the majority of WHO grades II and III diffuse gliomas, which can be further distinguished as oligodendroglial or astrocytic tumors by the presence or absence of 1p/19q codeletion. 2 We also found that CGI methylation of PRDX1 in 1p/19q codeleted gliomas was increased compared to non-codeleted IDH mutant or wildtype anaplastic gliomas. A recent study further revealed distinct oligodendroglioma subtypes that displayed mutant IDH and CIMP and either had a loss of 1p/19q or mutated TP53. Oligodendrogliomas with mutant TP53 showed astrocytic features and were more aggressive than their codeleted counterparts. 36 This is in line with our study since non-codeleted IDH-mutant gliomas exhibited lower PRDX1 CGI promoter methylation-and higher PRDX1 expression-levels than codeleted gliomas. When depleting PRDX1 in glioma cells, we saw a decrease in their invasive capability which may point to a role of PRDX1 in regulating the infiltrative growth of gliomas.
Peroxiredoxins are traditionally viewed as peroxide eliminators by directly discharging the oxidative equivalents to thioredoxin. 5 In addition to its function as an anti-oxidant enzyme, PRDX1 has been proposed to act as a chaperone.
37
Cys83 of PRDX1, which is unique among the human 2-Cysperoxidases, 37 mediates the formation of a decameric PRDX1 complex that is thought to increase chaperone activity. 38, 39 However, Cys83 may also be important for the ability of PRDX1 to form disulfide bonds with other proteins, such as p38a. Our experiments indicate that PRDX1 forms a heterodimer with p38a and that interaction is abrogated when either Cys83 of PRDX1 or Cys39 of p38a is mutated. Such a heterodimer has also been found in yeast, consisting of the PRDX1 homolog Tpx1 and the p38a homolog Sty1. Tpx1-Sty1 heterodimers showed a similar mobility shift to 70 kDa as observed for PRDX1-p38a. Heterodimer formations have also been observed between PRDX2 and STAT3, where the peroxiredoxin converts STAT3 monomers into oligomers of increased transcriptional activity. 40 However, the heterodimers formed by Tpx1 or PRDX2 are different: the peroxidatic cysteines are required whereas PRDX1 uses its unique non-peroxidatic Cys83. Further crystallization studies are required to obtain more conclusive data about the molecular structure and formation of the PRDX1-p38a heterodimer.
Loss of PRDX1 expression alone was sufficient for a downregulated MET/HGF pathway activity in IDH-wildtype gliomas. This is in line with previous studies demonstrating the influence of peroxiredoxins on signaling driven by receptor tyrosine kinases such as PDGFR or EGFR. 5 However, instead of using its peroxidase function, we found that PRDX1 regulated MET/HGF signaling by engaging p38a via the non-peroxidatic Cys83 to stabilize phosphorylation of the MAP kinase. Such an interaction had been described for the yeast homologs of PRDX1 and p38a, 7 yet, the functional consequence of this interaction for cancer-related signaling pathways has been unknown so far. Recently, inhibitors against PRDX1 have been developed that may be used for tumor treatment. 41, 42 However, PRDX1 is expressed in many tissues and its knock-out in mice induced severe oxidative damage, which led to the development of malignant tumors. 31 Thus, the administration of PRDX1 inhibitors might cause unspecific off-target effects. However, these effects may be avoided by directly targeting tumor-specific signaling pathways that depend on PRDX1. We found that the elevated MET/HGF pathway activity in gliomas was attenuated upon PRDX1 depletion. However, further treatment with MET kinase inhibitors did not have additive effects on MET/HGF signaling, suggesting that patients with CGI methylation or reduced expression of PRDX1 (i.e., in 1p/19q codeleted gliomas) would benefit less from a MET/ HGF-targeted tumor therapy. Furthermore, patients with codeleted gliomas seem to respond well to alkylating drugs. 22 This might be due to the tumors reduced invasive capability that shifts their cell fate decision toward cell division, rendering them more susceptible to cytostatic therapy. [43] [44] [45] [46] 
Conclusion
Since MET/HGF inhibitors only modestly improved survival in unselected populations, 11, 47 there is a need for reliable biomarkers that identify gliomas with active c-MET signaling. Our data show that PRDX1 supports c-MET signaling by sustaining phosphorylation of p38 and that PRDX1-depleted tumors do not respond to c-MET inhibition. Thus, PRDX1 may be a biomarker to identify patients that might respond favorably to inhibitors of the MET pathway.
